Company profile: Exelixis
1.1 - Company Overview
Company description
- Provider of therapies for cancer and other serious diseases, discovering, developing and commercializing small-molecule and biotherapeutic treatments. Marketed products include CABOMETYX (cabozantinib) and COTELLIC (cobimetinib); MINNEBRO (esaxerenone) is marketed in Japan by Daiichi Sankyo. Offers clinical trials, early access to investigational medicines, and collaborations to advance experimental molecules.
Products and services
- CABOMETYX (cabozantinib): Delivers a commercial oncology product treating multiple cancer types, focusing on small-molecule therapeutics for cancer management
- Clinical Trials and Pipeline: Advances clinical-stage development and trials for a range of cancer compounds, including small molecules and biotherapeutics, creating investigational programs
- COTELLIC (cobimetinib): Supplies tablet-form cancer treatment as part of Exelixis’s marketed products, offering a defined dosage format for oncology care
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Exelixis
TCR2 Therapeutics
HQ: United States
Website
- Description: Provider of a unique proprietary TRuC™ platform developed by a discovery-stage pharmaceutical company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TCR2 Therapeutics company profile →
Proxima Therapeutics
HQ: United States
Website
- Description: Provider of radiation delivery systems for treating solid cancerous tumors, with an initial focus on brain and breast cancer, including the GliaSite RTS for brain cancer and the MammoSite RTS for breast cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Proxima Therapeutics company profile →
Sierra Oncology
HQ: United States
Website
- Description: Provider of targeted cancer therapeutics in clinical development, focused on rare forms of cancer. Leverages deep scientific expertise to identify compounds that target root causes of disease and advances therapies using an evidence-based approach.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sierra Oncology company profile →
Vaxess
HQ: United States
Website
- Description: Provider of needle-free vaccine and therapeutic delivery solutions, offering the MIMIX applicator with patch for skin-based administration and silk fibroin biomaterials that create stable, biocompatible delivery systems, with a focus on improving access to vaccines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vaxess company profile →
RITA Medical Systems
HQ: United States
Website
- Description: Provider of innovative tumor ablation products, developing, manufacturing and marketing the proprietary RITA system, which uses radiofrequency energy to heat tissue to ablate it or cause cell death, with a current focus on liver cancer and metastatic bone cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full RITA Medical Systems company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Exelixis
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Exelixis
2.2 - Growth funds investing in similar companies to Exelixis
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Exelixis
4.2 - Public trading comparable groups for Exelixis
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →